Fig. 2: Overall survival and time on T-DXd in a series of 8 patients with breast cancer HER2 + leptomeningeal metastases.

Swimmers plot depicting time on treatment, best response by formal neuroradiology review and overall survival in patients with HER2+ LM treated with T-DXd.